EF Hutton Initiates Coverage On Marinus Pharma with Buy Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Marinus Pharma with a Buy rating and set a price target of $23, indicating a positive outlook for the company's stock.
September 30, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on Marinus Pharma with a Buy rating and a price target of $23, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $23 by EF Hutton is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100